Spain-based clothing retailer Zara will make its products available to online shoppers in an additional 106 countries, many of them in Africa, parent firm Inditex announced on Wednesday.
Reported by Reuters India 4 hours ago.
Zara goes online in 106 more countries, shares soar
↧
↧
Oldest known animal drawing found in remote Indonesian cave
WASHINGTON (AP) — Scientists have found the oldest known example of an animal drawing: a red silhouette of a bull-like beast on the wall of a remote Indonesian cave. The sketch is at least 40,000 years old, slightly older than similar animal paintings found in famous caves in France and Spain. Until a few years ago, experts believed Europe was where our ancestors started drawing animals and other figures. But the age of the drawing reported Wednesday in the journal Nature, along with previous discoveries in Southeast Asia, suggest that figurative drawing appeared in both continents about the same time.
Reported by SeattlePI.com 3 hours ago.
↧
The places every daring traveller should visit, unveiled in new book Atlas of the Unexpected
British author Travis Elborough’s new Atlas of the Unexpected: Haphazard Discoveries, Chance Places and Unimaginable Destinations features dozens of locations with potential to excite the interest of even the most jaded traveller. From the spectacularly palatial but abandoned Canfranc International railway station, in Spain, to the remote-but-reachable volcanic island of Aogashima, in Japan, it offers inspiration for travels beyond the usually safe and unsurprising annual travel lists...
Reported by S.China Morning Post 3 hours ago.
↧
Assale on target, Sanogo dismissed as Young Boys suffer UCL defeat vs. Valencia
The Cote d'Ivoire striker scored the leveller for his side, but they were eventually outclassed in Spain
Reported by Goal.com 2 hours ago.
↧
Queen Letizia of Spain attends a glittering reception in Valencia
The Queen of Spain stepped out in a fitted black jumpsuit as she joined King Felipe VI at the 'Noche De la Economia Valenciana' reception on Wednesday.
Reported by MailOnline 1 hour ago.
↧
↧
Valencia wins to stay in contention in Champions League
VALENCIA, Spain (AP) — Valencia ended its winless drought at home with a 3-1 victory over Young Boys 3-1 on Wednesday in the Champions League.Santi Mina scored twice in the first half and Carlos Soler added a goal after halftime...
Reported by New Zealand Herald 2 hours ago.
↧
Grenade-shaped belt buckle halts busy Madrid to Barcelona train link
A hand grenade-shaped belt buckle in the suitcase of a train passenger triggered major disruptions Wednesday on rail services in Spain's two main cities, prompting station evacuations before police declared the incident a false alarm.An...
Reported by New Zealand Herald 1 hour ago.
↧
BBVA Leads Blockchain-Based Syndicated Loan of $150 Million with BNP Paribas and MUFG
Spain’s 2nd greatest financial institution, Banco Bilbao Vizcaya Argentaria (BBVA), has performed a blockchain-based syndicated mortgage of $150 million, U.Okay.-based international monetary information company Finextra studies Wednesday, Nov. 7. The syndicated financial institution transaction has been carried out on a personal blockchain community thru a gaggle of 3 investment banks together with French banking workforce …
Reported by The News Articles 43 minutes ago.
↧
Solari's claim on Madrid coaching job faces test at Celta
BARCELONA, Spain (AP) — When Real Madrid visits Celta Vigo on Sunday, interim coach Santiago Solari may have his last chance to convince the club that he should stay on the job. Solari has steered Madrid to three wins since he was promoted from reserve team last week to replace Julen Lopetegui with the team in slump and coming off a 5-1 rout by Barcelona. By indicating Solari was taking over “provisionally", Madrid made it clear that it was still searching for a permanent replacement. Media speculation placed Antonio Conte, Roberto Martinez, Mauricio Pochettino, and even former Madrid coach Jose Mourinho on the list...
Reported by WorldNews 3 hours ago.
↧
↧
Spain 3-y Bond Auction: 0.102% vs previous 0.126%
Reported by FXstreet.com 8 hours ago.
↧
Spain 5-y Bond Auction down to 0.565% from previous 0.613%
Reported by FXstreet.com 8 hours ago.
↧
Man arrested on suspicion of planning attack on Spanish PM
BARCELONA, Spain (AP) — Spanish police say they have arrested a man who they believe intended to attack Spanish Prime Minister Pedro Sanchez over his controversial decision to exhume the remains of late dictator Gen. Francisco Franco.Police...
Reported by New Zealand Herald 8 hours ago.
↧
Belatrix CEO And Co-Founder, Luis Robbio, Wins Executive Of The Year
The Mendoza Executive Association Recognized Luis Robbio As Its Executive Of The Year
MENDOZA, Argentina (PRWEB) November 08, 2018
Belatrix Software, a leading software development company, is pleased to announce that its CEO and Co-Founder, Luis Robbio, has been recognized as “Executive of the Year” by the Mendoza Executive Association (AEM). The awards aim to recognize local entrepreneurs who contribute to the economic growth of Mendoza.
Federico Robbio, Belatrix President, Finance and Talent, and Co-Founder, accepted the award on behalf of Luis Robbio. The event took place at a gala ceremony in the InterContinental Hotel in Mendoza. The governor of Mendoza, Alfredo Cornejo, attended the ceremony.
This award follows on from Belatrix being recognized as a top place to work by the organization Great Place to Work and as a great employer in the American Business Awards. Belatrix continues its fast growth, recently opening its first European office in Spain. Earlier this year, Belatrix held the inauguration ceremony of its Colombia office in Bogotá.
Luis Robbio, commented, “I’m delighted to receive the award as executive of the year. I want to dedicate it to my sons, Alex and Federico, our partners, everyone at Belatrix including our management team, and our clients, who help make our success possible. We all share the challenges, but also our achievements together – I’m proud to be part of such an incredible group of individuals.
“It’s a very exciting time in the technology industry, as executives look to conduct digital transformations of their organizations. But to do this successfully, they need new skills and new capabilities. With our experience, we are well positioned to help organizations in their digital journeys”. Reported by PRWeb 8 hours ago.
MENDOZA, Argentina (PRWEB) November 08, 2018
Belatrix Software, a leading software development company, is pleased to announce that its CEO and Co-Founder, Luis Robbio, has been recognized as “Executive of the Year” by the Mendoza Executive Association (AEM). The awards aim to recognize local entrepreneurs who contribute to the economic growth of Mendoza.
Federico Robbio, Belatrix President, Finance and Talent, and Co-Founder, accepted the award on behalf of Luis Robbio. The event took place at a gala ceremony in the InterContinental Hotel in Mendoza. The governor of Mendoza, Alfredo Cornejo, attended the ceremony.
This award follows on from Belatrix being recognized as a top place to work by the organization Great Place to Work and as a great employer in the American Business Awards. Belatrix continues its fast growth, recently opening its first European office in Spain. Earlier this year, Belatrix held the inauguration ceremony of its Colombia office in Bogotá.
Luis Robbio, commented, “I’m delighted to receive the award as executive of the year. I want to dedicate it to my sons, Alex and Federico, our partners, everyone at Belatrix including our management team, and our clients, who help make our success possible. We all share the challenges, but also our achievements together – I’m proud to be part of such an incredible group of individuals.
“It’s a very exciting time in the technology industry, as executives look to conduct digital transformations of their organizations. But to do this successfully, they need new skills and new capabilities. With our experience, we are well positioned to help organizations in their digital journeys”. Reported by PRWeb 8 hours ago.
↧
↧
Spain 10-y Obligaciones Auction remains unchanged at 1.644%
Reported by FXstreet.com 7 hours ago.
↧
Sterilization Equipment - The Global Market (2018-2023) is Forecast to Grow at a CAGR of 7% During the Forecast Period
Dublin, Nov. 08, 2018 (GLOBE NEWSWIRE) -- The "Sterilization Equipment Market By Product And Service [Equipment (Moist Heat, Dry Heat, Hydrogen Peroxide, Ethylene Oxide), Consumables (Sterilization Indicators, Sterilant Cassettes), Services (E-Beam, EtO, Gamma)] - Global Forecast To 2023" report has been added to *ResearchAndMarkets.com's* offering.The global sterilization market is expected to grow at a CAGR of 7% from 2018 to reach USD 10.51 billion by 2023, driven by the factors such as increasing volume of surgeries performed globally, growing need to reduce occurrences of HAIs, and focus on reducing the cost of healthcare by minimizing hospital readmissions attributed to HAIs.
Furthermore, the technological advancements in the medical device industry and increasing need for advanced sterilization equipment are expected to drive the technological growth of the sterilization equipment market by 2023.
The low temperature sterilizers segment dominated the sterilization equipment market. However, the radiation sterilization segment comprising, e-beam and gamma sterilizers is expected to grow at the fastest CAGR during the forecast period, owing to their benefits, such as shorter sterilization cycle time, lower cost of sterilization, and compatibility with majority of the advanced medical devices available in the market.
An in-depth analysis of the geographical scenario of the industry provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) along with the coverage of major countries in each region. North America accounted for the largest share of the sterilization technologies market in 2017.
However, during the forecast period, the APAC market is expected to register the fastest CAGR. The growth in this geographic market is primarily attributed to the government initiatives to improve healthcare infrastructure in this region, increasing number of hospitals in this region, and rising number of surgeries being performed and thereby growing demand for sterilized instruments. India and China represent the fastest growing markets in this region and globally as well.
The major players operating in the sterilization technologies market are Steris, Getinge, Sotera Health, Advanced Sterilization Products, 3M, Belimed, MMM Group, Matachana Group, and Cantel Medical.
While there are numerous regional and local players in the sterilization equipment and consumables market, the contract sterilization services market is dominated by Steris and Sotera Health.
Some of the other key players in the contract sterilization services market are Cretex Companies, Medistri, COSMED Group, E-BEAM Services, Cantel Medical, Stryker Corporation, and Centurion Medical Products.
*Key Topics Covered**1. Introduction*
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency and Limitations
1.3.1. Currency
1.3.2. Limitations
1.4. Key Stakeholders
*2. Research Methodology*
2.1. Research Process
2.1.1. Secondary Research
2.1.2. Primary Research
2.1.3. Market Size Estimation
*3. Executive Summary*
3.1. Introduction
3.2. Market Dynamics
3.3. Product Segment Analysis
3.4. Regional Analysis
3.5. Competitive Analysis
*4. Market Overview*
4.1. Overview
4.2. Drivers
4.2.1. Growing Need to Curtail Hospital-Acquired Infections
4.2.2. Growth in the Number of Surgical Procedures
4.2.3. Rising Demand of Sterilization in Food Industry to Prevent Food-Borne Diseases
4.2.4. Increasing Sterilization Demand from Pharmaceutical and Biotechnology Industries
4.3. Restraints
4.3.1. Harmful Effects of Ethylene Oxide
4.3.2. Concerns Regarding the Safety of Reprocessed Instruments
4.4. Opportunities
4.4.1. Growing Demand of Sterilization Technologies in Emerging Markets
4.4.2. Rising Demand for E-Beam Sterilization
4.5. Challenges
4.5.1. Growing Adoption of Advanced Medical Instruments Driving Complexity of Sterilization
4.5.2. End-User Noncompliance with Sterilization Standards
*5. Sterilization Equipment Market, by Technology*
5.1. Overview
5.2. Heat Sterilization Equipment
5.2.1. Moist Heat Sterilizers
5.2.2. Dry Heat Sterilizers
5.3. Low Temperature Sterilization Equipment
5.3.1. Hydrogen Peroxide / Gas Plasma Sterilizers
5.3.2. Ethylene Oxide Sterilizers
5.3.3. Ozone-Based Sterilizers
5.3.4. Formaldehyde Sterilizers
5.3.5. Other Low Temperature Sterilizers
5.4. Radiation Sterilization Equipment
5.5. Filtration Sterilization Equipment
*6. Sterilization Consumables Market, by Product*
6.1. Overview
6.2. Sterilization Indicators
6.3. Sterilant Cassettes
6.4. Other Sterilization Consumables & Accessories
*7. Sterilization Services Market, by Type*
7.1. Overview
7.2. Ethylene Oxide Sterilization Services
7.3. Gamma Sterilization Services
7.4. E-Beam Sterilization Services
7.5. Steam Sterilization Services
7.6. Other Sterilization Services
*8. Sterilization Technologies Market, by End User*
8.1. Overview
8.2. Hospitals and Clinics
8.3. Medical Device Companies
8.4. Food and Beverages Industry
8.5. Pharmaceutical Companies
8.6. Other End Users
*9. Sterilization Technologies Market, by Region*
9.1. Overview
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. United Kingdom
9.3.2. Germany
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Rest of Asia Pacific
9.5. Latin America
9.6. Middle East & Africa
*10. Competitive Outlook*
10.1. Competitor Benchmarking
10.2. Market Share Analysis
*11. Company Profiles*
11.1. Steris Corporation
11.2. 3M Company
11.3. Getinge AB
11.4. MMM Group
11.5. Belimed AG (Subsidiary of Metall Zug Group)
11.6. Matachana Group
11.7. Sotera Health
11.8. Cardinal Health
11.9. Advanced Sterilization Products (J&J)
11.10. Cantel MedicalFor more information about this report visit https://www.researchandmarkets.com/research/7pbcvw/sterilization?w=12
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Medical Devices Reported by GlobeNewswire 7 hours ago.
Furthermore, the technological advancements in the medical device industry and increasing need for advanced sterilization equipment are expected to drive the technological growth of the sterilization equipment market by 2023.
The low temperature sterilizers segment dominated the sterilization equipment market. However, the radiation sterilization segment comprising, e-beam and gamma sterilizers is expected to grow at the fastest CAGR during the forecast period, owing to their benefits, such as shorter sterilization cycle time, lower cost of sterilization, and compatibility with majority of the advanced medical devices available in the market.
An in-depth analysis of the geographical scenario of the industry provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) along with the coverage of major countries in each region. North America accounted for the largest share of the sterilization technologies market in 2017.
However, during the forecast period, the APAC market is expected to register the fastest CAGR. The growth in this geographic market is primarily attributed to the government initiatives to improve healthcare infrastructure in this region, increasing number of hospitals in this region, and rising number of surgeries being performed and thereby growing demand for sterilized instruments. India and China represent the fastest growing markets in this region and globally as well.
The major players operating in the sterilization technologies market are Steris, Getinge, Sotera Health, Advanced Sterilization Products, 3M, Belimed, MMM Group, Matachana Group, and Cantel Medical.
While there are numerous regional and local players in the sterilization equipment and consumables market, the contract sterilization services market is dominated by Steris and Sotera Health.
Some of the other key players in the contract sterilization services market are Cretex Companies, Medistri, COSMED Group, E-BEAM Services, Cantel Medical, Stryker Corporation, and Centurion Medical Products.
*Key Topics Covered**1. Introduction*
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency and Limitations
1.3.1. Currency
1.3.2. Limitations
1.4. Key Stakeholders
*2. Research Methodology*
2.1. Research Process
2.1.1. Secondary Research
2.1.2. Primary Research
2.1.3. Market Size Estimation
*3. Executive Summary*
3.1. Introduction
3.2. Market Dynamics
3.3. Product Segment Analysis
3.4. Regional Analysis
3.5. Competitive Analysis
*4. Market Overview*
4.1. Overview
4.2. Drivers
4.2.1. Growing Need to Curtail Hospital-Acquired Infections
4.2.2. Growth in the Number of Surgical Procedures
4.2.3. Rising Demand of Sterilization in Food Industry to Prevent Food-Borne Diseases
4.2.4. Increasing Sterilization Demand from Pharmaceutical and Biotechnology Industries
4.3. Restraints
4.3.1. Harmful Effects of Ethylene Oxide
4.3.2. Concerns Regarding the Safety of Reprocessed Instruments
4.4. Opportunities
4.4.1. Growing Demand of Sterilization Technologies in Emerging Markets
4.4.2. Rising Demand for E-Beam Sterilization
4.5. Challenges
4.5.1. Growing Adoption of Advanced Medical Instruments Driving Complexity of Sterilization
4.5.2. End-User Noncompliance with Sterilization Standards
*5. Sterilization Equipment Market, by Technology*
5.1. Overview
5.2. Heat Sterilization Equipment
5.2.1. Moist Heat Sterilizers
5.2.2. Dry Heat Sterilizers
5.3. Low Temperature Sterilization Equipment
5.3.1. Hydrogen Peroxide / Gas Plasma Sterilizers
5.3.2. Ethylene Oxide Sterilizers
5.3.3. Ozone-Based Sterilizers
5.3.4. Formaldehyde Sterilizers
5.3.5. Other Low Temperature Sterilizers
5.4. Radiation Sterilization Equipment
5.5. Filtration Sterilization Equipment
*6. Sterilization Consumables Market, by Product*
6.1. Overview
6.2. Sterilization Indicators
6.3. Sterilant Cassettes
6.4. Other Sterilization Consumables & Accessories
*7. Sterilization Services Market, by Type*
7.1. Overview
7.2. Ethylene Oxide Sterilization Services
7.3. Gamma Sterilization Services
7.4. E-Beam Sterilization Services
7.5. Steam Sterilization Services
7.6. Other Sterilization Services
*8. Sterilization Technologies Market, by End User*
8.1. Overview
8.2. Hospitals and Clinics
8.3. Medical Device Companies
8.4. Food and Beverages Industry
8.5. Pharmaceutical Companies
8.6. Other End Users
*9. Sterilization Technologies Market, by Region*
9.1. Overview
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. United Kingdom
9.3.2. Germany
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Rest of Asia Pacific
9.5. Latin America
9.6. Middle East & Africa
*10. Competitive Outlook*
10.1. Competitor Benchmarking
10.2. Market Share Analysis
*11. Company Profiles*
11.1. Steris Corporation
11.2. 3M Company
11.3. Getinge AB
11.4. MMM Group
11.5. Belimed AG (Subsidiary of Metall Zug Group)
11.6. Matachana Group
11.7. Sotera Health
11.8. Cardinal Health
11.9. Advanced Sterilization Products (J&J)
11.10. Cantel MedicalFor more information about this report visit https://www.researchandmarkets.com/research/7pbcvw/sterilization?w=12
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Medical Devices Reported by GlobeNewswire 7 hours ago.
↧
Global Cancer Immunotherapy Market by Type, Application and End-User (2018-2024) - High Growth Prospects in Emerging Economies
Dublin, Nov. 08, 2018 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Market By Type (Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy), Application (Lung, Breast, Multiple Myeloma, Colorectal, Melanoma, Prostate), And End User- Global Forecast To 2024" report has been added to *ResearchAndMarkets.com's* offering.The global cancer immunotherapy market is expected to grow at a CAGR of 13.8% from 2018 to reach USD 152.83 billion by 2024.
The high growth of cancer immunotherapy market is attributed to factors such as rising incidence of cancer globally, rising adoption of cancer immunotherapies over other conventional cancer treatments owing to the increased survival rate and less side effects with immunotherapy drugs, increasing number of ongoing clinical trials with the help of rising investments by major players in the market, and development of bioinformatics tools that are enhancing the drug development process for cancer immunotherapy market.
However, the high cost of the cancer immunotherapy treatment is restricting the growth of this market to some extent. Apart from this, growing R&D investments by major players in the market to develop cancer immunotherapies and high growth prospects in the developing countries such as China and India provides significant opportunity in this market.
Monoclonal antibodies dominated the global cancer immunotherapy market, mainly due to their high adoption for cancer treatment, rising number of US FDA approvals, and better five-year survival rates as compared to other cancer treatment options available in the market.
Cancer immunotherapy market for lung cancer application commanded the largest share, mainly attributed to increasing incidence of lung cancer, the significant benefit of cancer immunotherapy for lung cancer compared with other treatment options, and rising adoption of immunotherapies in lung cancer owing to the higher survival rate.North America commanded the largest share of the global cancer immunotherapy market in 2017, followed by Europe and the Asia Pacific region. The large share of this region is mainly attributed to the factors such as rising incidence of cancer globally, growing adoption of immunotherapy for cancer treatment, rising investments in collaboration and mergers, and enhancement in the drug development process owing to the development of bioinformatics.
Furthermore, the regulatory bodies such as US FDA and European Commission are specially focusing on the research of cancer immunotherapy due to the advantages of this therapy compared with other treatment options. The faster drug approval in the cancer immunotherapy is also responsible for the growth of this market.*Key Topics Covered**1. Introduction*
1.1. Market Definition
1.2. Market Segmentation
1.3. Currency and Limitations
1.3.1. Currency
1.3.2. Limitations
1.4. Key Stakeholders
*2. Research Methodology*
2.1. Research Process
2.1.1. Secondary Research
2.1.2. Primary Research
2.1.3. Market Size Estimation
*3. Executive Summary*
3.1. Introduction
3.2. Market Dynamics
3.3. Product Segment Analysis
3.4. Application Segment Analysis
3.5. End User Analysis
3.6. Regional Analysis
3.7. Competitive Analysis
*4. Market Overview*
4.1. Introduction
4.2. Drivers
4.2.1. Rising Cancer Incidence
4.2.2. Growing Adoption of Immunotherapy over other Treatment Options
4.2.3. Increasing Number of Technological Collaborations and Mergers
4.2.4. Development of Bioinformatics Tools Enhancing Drug Development Process
4.3. Market Restraints
4.3.1. High Cost of Treatment
4.4. Market Opportunities
4.4.1. Growing R&D Expenditure
4.4.2. High Growth Prospects in Emerging Economies
4.5. Market Challenges
4.5.1. Limited Funds with Small and Mid-Sized Organizations to Initiate the Clinical Trials
4.5.2. Complexities of Tumor
*5. Industry Insights*
5.1. Key Industry Trends
5.1.1. Personalized Immunotherapy
5.1.2. Implementation of Next-Generation Sequencing Technologies
5.1.3. Immunotherapy Combination
5.1.4. Accelerated Approval
5.1.5. China's Rapidly Expanding Cancer Immunotherapy Market
5.2. Evolution of Cancer Immunotherapy
5.3. Opdivo and Keytruda: Major Products in Cancer Immunotherapy Market
*6. Cancer Immunotherapy Market, by Type*
6.1. Introduction
6.2. Monoclonal Antibodies
6.3. Checkpoint Inhibitors
6.4. Immunomodulators
6.5. Vaccines
6.6. Cell Therapies
*7. Cancer Immunotherapy Market, by Application*
7.1. Introduction
7.2. Lung Cancer
7.3. Breast Cancer
7.4. Colorectal Cancer
7.5. Melanoma
7.6. Prostate Cancer
7.7. Multiple Myeloma
7.8. Other Cancer Types
*8. Cancer Immunotherapy Market, by End User*
8.1. Overview
8.2. Hospitals
8.3. Clinics and Others
*9. Cancer Immunotherapy Market, by Region*
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Asia Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Rest of Asia Pacific
9.5. Latin America
9.6. Middle East & Africa
*10. Competitive Landscape*
10.1. Introduction
10.2. Market Share Analysis
10.3. Competitor Benchmarking
10.4. Competitive Situation and Trends
10.4.1. Approvals
10.4.2. Agreements and Collaborations
10.4.3. Acquisitions
10.4.4. Other Developments
*11. Company Profiles*
11.1. Astrazeneca
11.2. Amgen
11.3. Bristol-Myers Squibb
11.4. Eli Lilly
11.5. Johnson & Johnson
11.6. Merck & Co., Inc.
11.7. Novartis International AG
11.8. Pfizer Inc.
11.9. F. Hoffmann-La Roche
11.10. Celgene CorporationFor more information about this report visit https://www.researchandmarkets.com/research/7cgsnc/global_cancer?w=12
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Genomics, Immune Disorders Drugs, Biopharmaceuticals , Hematology , Cancer Vaccines, Immunosuppressive Drugs Reported by GlobeNewswire 7 hours ago.
The high growth of cancer immunotherapy market is attributed to factors such as rising incidence of cancer globally, rising adoption of cancer immunotherapies over other conventional cancer treatments owing to the increased survival rate and less side effects with immunotherapy drugs, increasing number of ongoing clinical trials with the help of rising investments by major players in the market, and development of bioinformatics tools that are enhancing the drug development process for cancer immunotherapy market.
However, the high cost of the cancer immunotherapy treatment is restricting the growth of this market to some extent. Apart from this, growing R&D investments by major players in the market to develop cancer immunotherapies and high growth prospects in the developing countries such as China and India provides significant opportunity in this market.
Monoclonal antibodies dominated the global cancer immunotherapy market, mainly due to their high adoption for cancer treatment, rising number of US FDA approvals, and better five-year survival rates as compared to other cancer treatment options available in the market.
Cancer immunotherapy market for lung cancer application commanded the largest share, mainly attributed to increasing incidence of lung cancer, the significant benefit of cancer immunotherapy for lung cancer compared with other treatment options, and rising adoption of immunotherapies in lung cancer owing to the higher survival rate.North America commanded the largest share of the global cancer immunotherapy market in 2017, followed by Europe and the Asia Pacific region. The large share of this region is mainly attributed to the factors such as rising incidence of cancer globally, growing adoption of immunotherapy for cancer treatment, rising investments in collaboration and mergers, and enhancement in the drug development process owing to the development of bioinformatics.
Furthermore, the regulatory bodies such as US FDA and European Commission are specially focusing on the research of cancer immunotherapy due to the advantages of this therapy compared with other treatment options. The faster drug approval in the cancer immunotherapy is also responsible for the growth of this market.*Key Topics Covered**1. Introduction*
1.1. Market Definition
1.2. Market Segmentation
1.3. Currency and Limitations
1.3.1. Currency
1.3.2. Limitations
1.4. Key Stakeholders
*2. Research Methodology*
2.1. Research Process
2.1.1. Secondary Research
2.1.2. Primary Research
2.1.3. Market Size Estimation
*3. Executive Summary*
3.1. Introduction
3.2. Market Dynamics
3.3. Product Segment Analysis
3.4. Application Segment Analysis
3.5. End User Analysis
3.6. Regional Analysis
3.7. Competitive Analysis
*4. Market Overview*
4.1. Introduction
4.2. Drivers
4.2.1. Rising Cancer Incidence
4.2.2. Growing Adoption of Immunotherapy over other Treatment Options
4.2.3. Increasing Number of Technological Collaborations and Mergers
4.2.4. Development of Bioinformatics Tools Enhancing Drug Development Process
4.3. Market Restraints
4.3.1. High Cost of Treatment
4.4. Market Opportunities
4.4.1. Growing R&D Expenditure
4.4.2. High Growth Prospects in Emerging Economies
4.5. Market Challenges
4.5.1. Limited Funds with Small and Mid-Sized Organizations to Initiate the Clinical Trials
4.5.2. Complexities of Tumor
*5. Industry Insights*
5.1. Key Industry Trends
5.1.1. Personalized Immunotherapy
5.1.2. Implementation of Next-Generation Sequencing Technologies
5.1.3. Immunotherapy Combination
5.1.4. Accelerated Approval
5.1.5. China's Rapidly Expanding Cancer Immunotherapy Market
5.2. Evolution of Cancer Immunotherapy
5.3. Opdivo and Keytruda: Major Products in Cancer Immunotherapy Market
*6. Cancer Immunotherapy Market, by Type*
6.1. Introduction
6.2. Monoclonal Antibodies
6.3. Checkpoint Inhibitors
6.4. Immunomodulators
6.5. Vaccines
6.6. Cell Therapies
*7. Cancer Immunotherapy Market, by Application*
7.1. Introduction
7.2. Lung Cancer
7.3. Breast Cancer
7.4. Colorectal Cancer
7.5. Melanoma
7.6. Prostate Cancer
7.7. Multiple Myeloma
7.8. Other Cancer Types
*8. Cancer Immunotherapy Market, by End User*
8.1. Overview
8.2. Hospitals
8.3. Clinics and Others
*9. Cancer Immunotherapy Market, by Region*
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Asia Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Rest of Asia Pacific
9.5. Latin America
9.6. Middle East & Africa
*10. Competitive Landscape*
10.1. Introduction
10.2. Market Share Analysis
10.3. Competitor Benchmarking
10.4. Competitive Situation and Trends
10.4.1. Approvals
10.4.2. Agreements and Collaborations
10.4.3. Acquisitions
10.4.4. Other Developments
*11. Company Profiles*
11.1. Astrazeneca
11.2. Amgen
11.3. Bristol-Myers Squibb
11.4. Eli Lilly
11.5. Johnson & Johnson
11.6. Merck & Co., Inc.
11.7. Novartis International AG
11.8. Pfizer Inc.
11.9. F. Hoffmann-La Roche
11.10. Celgene CorporationFor more information about this report visit https://www.researchandmarkets.com/research/7cgsnc/global_cancer?w=12
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Genomics, Immune Disorders Drugs, Biopharmaceuticals , Hematology , Cancer Vaccines, Immunosuppressive Drugs Reported by GlobeNewswire 7 hours ago.
↧
Xiaomi launches in the UK with Mi 8 Pro flagship
Xiaomi’s international expansion is taking a major step forward today with the Chinese company’s debut in the United Kingdom. A year and a day after launching a range of products in Spain, Xiaomi’s European foray is arriving in the UK, headlined by the Xiaomi Mi 8 Pro Android flagship phone and the opening of an Authorized Mi Store in the Westfield shopping center in London.Europe has proven highly receptive to Xiaomi’s charms of high-spec devices at breakthrough prices. The company has 10 stores up and running in Spain, it expanded into France and Italy in May, and now it’s coming to one of the biggest and most hotly contested consumer electronics markets in the region.
Speaking to The Verge ahead of today’s announcement, Xiaomi... Reported by The Verge 7 hours ago.
↧
↧
Pochettino reaffirms Spurs commitment amid Real interest
Real sacked coach Julen Lopetegui last week and Pochettino's recent statement that he had his "worst feeling" at Tottenham in his four-and-a-half years at the club fuelled rumours that he could soon be on his way to Spain.
Reported by SBS 6 hours ago.
↧
KROMI publishes corrected statement on the first quarter of FY 2018/2019
DGAP-News: KROMI Logistik AG / Key word(s): Quarterly / Interim Statement
08.11.2018 / 17:13
The issuer is solely responsible for the content of this announcement.
--------------------
*KROMI publishes corrected statement on the first quarter of FY 2018/2019 *
*- Revenues in the amount of EUR 17,570 thousand achieved*
*- Operating result (EBIT) burdened with special effects at EUR -1,275 thousand*
*- Operating result (EBIT before special effects) at EUR -360 thousand*
*Hamburg, November 8, 2018 - KROMI, a manufacturer-independent expert in optimising tool availability and tool deployment in machining operations, generated revenue of EUR 17,570 thousand in the 2018/2019 fiscal year (previous year: EUR 19,162 thousand). The result from operations (EBIT) amounted to EUR **-1,275 thousand (previous year: EUR 627 thousand). *
Revenue development in the first quarter of 2018/2019 varied considerably from region to region. While KROMI continued to report a marked decrease in revenue in Germany due to the discontinuation of a contract with a major customer, foreign business performed well, and partly offset the reduced revenue in Germany. Revenue in Germany reduced by 22.8 percent from EUR 11,342 thousand in the previous year to EUR 8,756 thousand, reflecting the aforementioned ending of a contract with a major customer, which had still made a significant contribution to prior-year revenue. The operating business outside Germany performed well with an overall increase of 12.7 percent, with revenue in European countries outside Germany registering a 16.2 percent year-on-year increase to EUR 7,003 thousand (EUR 6,026 thousand). In Brazil, revenue in terms of the Brazilian currency, the real, amounted to BRL 8,408 thousand, representing 26.2 percent growth compared with the previous year (BRL 6,663 thousand). Due to the weak real, this development in euros failed to contribute to better Group results. Revenue grew from EUR 1,794 thousand in the previous year to EUR 1,811 thousand.
CEO Bernd Paulini comments: "Although by acquiring new customers as well as expanding the activities for existing customers we have already offset around 50 percent of the reduction in revenue from the discontinued contract, total revenue was nevertheless down significantly compared with the previous year's level. Our operating result - in other words, EBIT adjusted to reflect non-operating effects - amounted to EUR -360 thousand. In order to more efficiently leverage the future potentials of our markets and our business model, we are realigning our product strategy and introducing significant structural measures to secure growth as well as to establish a significantly improved cost structure. We are convinced that the new product strategy will lead to expanded market penetration. The result is additionally burdened by a provision of EUR 650 thousand, which had to be formed in connection with the departure of a member of the Management Board on March 31, 2019."
With the competency areas of Tools, Technology, Logistics and Data, KROMI will offer a spectrum of top technical performance, maximum availability and comprehensive transparency. In future customers can select the service portfolio that suits them best and offers them the highest benefit. After overcoming the currently difficult situation, due to the unique competences in machining processes and the business expertise to the customers' needs, the Management Board considers KROMI optimally positioned to meet the forthcoming challenges, and looks to the future with optimism.
Over the course of the day, KROMI will make the full and corrected (IFRS) report for the first three months of its 2018/2019 fiscal year available for downloading on its website at www.kromi.de within the Investor Relations area.
*Company profile: *
KROMI, Hamburg, is a manufacturer-independent expert in optimising tool availability and tool deployment in machining operations. As a reliable and transparent partner to industry, KROMI combines machining technology, data management and streamlined logistics processes to form compelling all-round solutions. Thanks to networked dispensers in customers' production areas in combination with digital inventory controlling, KROMI ensures the optimal utilisation and availability of the requisite working resources at the right time and in the right place. The activities of KROMI aim to always offer maximum value for customers' machining operations in its core markets of Europe and Brazil. This entails analysing processes on the customer side in detail and identifying opportunities and potential improvements, in order to optimally integrate tool supplies with all requisite services. KROMI currently has sites in Germany, Slovakia, the Czech Republic, Spain and Brazil. KROMI is also active in five further European countries.
Visit us on the Internet at:* *www.kromi.de
Investor relations contact:
cometis AG
Claudius Krause
Tel.: +49 (0)611-205855-28
Fax: +49 (0)611-205855-66
Email: krause@cometis.de
--------------------
08.11.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de --------------------
Language: English
Company: KROMI Logistik AG
Tarpenring 11
22419 Hamburg
Germany
Phone: 040/537151-0
Fax: 040/537151-99
E-mail: info@kromi.de
Internet: www.kromi.de
ISIN: DE000A0KFUJ5
WKN: A0KFUJ
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart
End of News DGAP News Service Reported by EQS Group 6 hours ago.
08.11.2018 / 17:13
The issuer is solely responsible for the content of this announcement.
--------------------
*KROMI publishes corrected statement on the first quarter of FY 2018/2019 *
*- Revenues in the amount of EUR 17,570 thousand achieved*
*- Operating result (EBIT) burdened with special effects at EUR -1,275 thousand*
*- Operating result (EBIT before special effects) at EUR -360 thousand*
*Hamburg, November 8, 2018 - KROMI, a manufacturer-independent expert in optimising tool availability and tool deployment in machining operations, generated revenue of EUR 17,570 thousand in the 2018/2019 fiscal year (previous year: EUR 19,162 thousand). The result from operations (EBIT) amounted to EUR **-1,275 thousand (previous year: EUR 627 thousand). *
Revenue development in the first quarter of 2018/2019 varied considerably from region to region. While KROMI continued to report a marked decrease in revenue in Germany due to the discontinuation of a contract with a major customer, foreign business performed well, and partly offset the reduced revenue in Germany. Revenue in Germany reduced by 22.8 percent from EUR 11,342 thousand in the previous year to EUR 8,756 thousand, reflecting the aforementioned ending of a contract with a major customer, which had still made a significant contribution to prior-year revenue. The operating business outside Germany performed well with an overall increase of 12.7 percent, with revenue in European countries outside Germany registering a 16.2 percent year-on-year increase to EUR 7,003 thousand (EUR 6,026 thousand). In Brazil, revenue in terms of the Brazilian currency, the real, amounted to BRL 8,408 thousand, representing 26.2 percent growth compared with the previous year (BRL 6,663 thousand). Due to the weak real, this development in euros failed to contribute to better Group results. Revenue grew from EUR 1,794 thousand in the previous year to EUR 1,811 thousand.
CEO Bernd Paulini comments: "Although by acquiring new customers as well as expanding the activities for existing customers we have already offset around 50 percent of the reduction in revenue from the discontinued contract, total revenue was nevertheless down significantly compared with the previous year's level. Our operating result - in other words, EBIT adjusted to reflect non-operating effects - amounted to EUR -360 thousand. In order to more efficiently leverage the future potentials of our markets and our business model, we are realigning our product strategy and introducing significant structural measures to secure growth as well as to establish a significantly improved cost structure. We are convinced that the new product strategy will lead to expanded market penetration. The result is additionally burdened by a provision of EUR 650 thousand, which had to be formed in connection with the departure of a member of the Management Board on March 31, 2019."
With the competency areas of Tools, Technology, Logistics and Data, KROMI will offer a spectrum of top technical performance, maximum availability and comprehensive transparency. In future customers can select the service portfolio that suits them best and offers them the highest benefit. After overcoming the currently difficult situation, due to the unique competences in machining processes and the business expertise to the customers' needs, the Management Board considers KROMI optimally positioned to meet the forthcoming challenges, and looks to the future with optimism.
Over the course of the day, KROMI will make the full and corrected (IFRS) report for the first three months of its 2018/2019 fiscal year available for downloading on its website at www.kromi.de within the Investor Relations area.
*Company profile: *
KROMI, Hamburg, is a manufacturer-independent expert in optimising tool availability and tool deployment in machining operations. As a reliable and transparent partner to industry, KROMI combines machining technology, data management and streamlined logistics processes to form compelling all-round solutions. Thanks to networked dispensers in customers' production areas in combination with digital inventory controlling, KROMI ensures the optimal utilisation and availability of the requisite working resources at the right time and in the right place. The activities of KROMI aim to always offer maximum value for customers' machining operations in its core markets of Europe and Brazil. This entails analysing processes on the customer side in detail and identifying opportunities and potential improvements, in order to optimally integrate tool supplies with all requisite services. KROMI currently has sites in Germany, Slovakia, the Czech Republic, Spain and Brazil. KROMI is also active in five further European countries.
Visit us on the Internet at:* *www.kromi.de
Investor relations contact:
cometis AG
Claudius Krause
Tel.: +49 (0)611-205855-28
Fax: +49 (0)611-205855-66
Email: krause@cometis.de
--------------------
08.11.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de --------------------
Language: English
Company: KROMI Logistik AG
Tarpenring 11
22419 Hamburg
Germany
Phone: 040/537151-0
Fax: 040/537151-99
E-mail: info@kromi.de
Internet: www.kromi.de
ISIN: DE000A0KFUJ5
WKN: A0KFUJ
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart
End of News DGAP News Service Reported by EQS Group 6 hours ago.
↧
Wisconsin native and Guatemalan martyr: Br. James Miller to be beatified
Vatican City, Nov 8, 2018 / 10:00 am (CNA).- Pope Francis Thursday approved the beatification of American Br. James Miller, who was martyred in 1982 in Guatemala.
The declarations were made following a meeting Nov. 7 with Cardinal Angelo Becciu, prefect of the Congregation for the Causes of the Saints. Pope Francis gave his approval for Miller’s beatification, declaring he was killed “in hatred of the faith,” and advancing 23 other causes for canonization.
The pope also confirmed the heroic virtue of Servant of God Michael Giedrojć and approved his beatification.
Now-Bl. Michael Giedrojć was a brother of the Order of St. Augustine born in Lithuania around the year 1420. He died in Krakow, Poland on May 4, 1485.
Giedrojć was approved through an “equivalent beatification,” a process by which the pope may declare a person to be a “blessed” without the typical investigation and miracle, due to a long-standing recognition of the person’s holiness and virtue, usually in the place where he or she lived, called a “local cult.” The same process may be used for a canonization.
Br. James Alfred Miller, who was a religious brother of the Institute of the Brothers of Christian Schools (called Christian Brothers) was serving in Guatemala when he was shot to death by three hooded men in the afternoon of Feb. 13, 1982, dying instantly. He was 37.
Miller, who was born near Stevens Point, Wisconsin in 1944, took the habit of the Christian Brothers in August 1962.
He coached football, and taught Spanish, English, and religion in a high school in St. Paul, Minn. There his construction and maintenance abilities gained him the nickname "Brother Fix-It."
Miller was later sent to teach in Nicaragua, where under his leadership a school grew from 300 to 800 students and he supervised the construction of 10 new rural schools.
In July 1978 his superiors asked him to leave the country because of the danger amid the Sandinista Revolution. He returned to the U.S. and again taught high school.
He was sent to mission territory in Guatemala in 1981, teaching at a secondary school and at a center for studies for young indigenous Mayans from rural areas.
He was assassinated in February 1982, while standing on a ladder, repairing a wall of a school building.
Local authorities did not identify the gunmen.
Miller’s killing was one in a string of assassinations of priests and religious in the country, including that of Bl. Stanley Rother five months later.
Aware of the danger present to him in Guatemala, in one of his last letters before he died, Miller wrote: “I am personally weary of violence, but I continue to feel a strong commitment to the suffering poor of Central America. …the Church is being persecuted because of its option for the poor.”
“Aware of numerous dangers and difficulties, we continue working with faith and hope and trusting in God’s Providence. … I pray to God for the grace and strength to serve Him faithfully among the poor and oppressed in Guatemala. I place my life in His Providence. I place my trust in Him.”
The date of Miller’s beatification has not been announced but is expected to take place sometime in 2019.
In addition to Miller, Pope Francis Nov. 8 declared the martyrdom of Angelo Cuartas Cristobal and eight companions, alumni of the Seminary of Oviedo, Spain, who were killed in Oviedo between 1934-1937; and Mariano Mullerat i Soldevila, a layman and father, who was killed near Arbeca, Spain in 1936.
The pope also recognized miracles attributed to Venerable Edvige Carboni (1880-1952) and Benedetta Bianchi Porro (1936-1964), paving the way for their beatification.
The heroic virtue of nine other Catholics was also declared, advancing their causes along the path of beatification.
They are: Italian Bishop Giovanni Jacono (1873-1957); Filipino Bishop Alfredo Maria Obviar, founder of the Congregation of the Missionary Catechists of St. Teresa of the Child Jesus (1889-1978); Italian Fr. Giovanni Ciresola, founder of the Congregation of the Poor Servants of the Most Precious Blood-Cenacle of Charity (1902-1987); Italian Fr. Luigi Bosio (1909-1994); Italian Fr. Luigi Maria Raineri, member of the Congregation of the Clerics Regular of St. Paul (1895-1918); Spanish Sr. Maria Antonia di Gesu, member of the Discalced Carmelites (1700-1760); Spanish Sr. Arcangela Badosa Cuatrecasas, member of the Congregation of the Sisters of the Blessed Virgin Mary of Mount Carmel (1878-1918); Italian Sr. Maria Addolorata del Sacro Costato of the Congregation of the Sisters of the Passion of Jesus Christ (1920-1954); and Italian Lodovico Coccapani, lay member of the Secular Franciscan Order (1849-1931).
Reported by CNA 5 hours ago.
The declarations were made following a meeting Nov. 7 with Cardinal Angelo Becciu, prefect of the Congregation for the Causes of the Saints. Pope Francis gave his approval for Miller’s beatification, declaring he was killed “in hatred of the faith,” and advancing 23 other causes for canonization.
The pope also confirmed the heroic virtue of Servant of God Michael Giedrojć and approved his beatification.
Now-Bl. Michael Giedrojć was a brother of the Order of St. Augustine born in Lithuania around the year 1420. He died in Krakow, Poland on May 4, 1485.
Giedrojć was approved through an “equivalent beatification,” a process by which the pope may declare a person to be a “blessed” without the typical investigation and miracle, due to a long-standing recognition of the person’s holiness and virtue, usually in the place where he or she lived, called a “local cult.” The same process may be used for a canonization.
Br. James Alfred Miller, who was a religious brother of the Institute of the Brothers of Christian Schools (called Christian Brothers) was serving in Guatemala when he was shot to death by three hooded men in the afternoon of Feb. 13, 1982, dying instantly. He was 37.
Miller, who was born near Stevens Point, Wisconsin in 1944, took the habit of the Christian Brothers in August 1962.
He coached football, and taught Spanish, English, and religion in a high school in St. Paul, Minn. There his construction and maintenance abilities gained him the nickname "Brother Fix-It."
Miller was later sent to teach in Nicaragua, where under his leadership a school grew from 300 to 800 students and he supervised the construction of 10 new rural schools.
In July 1978 his superiors asked him to leave the country because of the danger amid the Sandinista Revolution. He returned to the U.S. and again taught high school.
He was sent to mission territory in Guatemala in 1981, teaching at a secondary school and at a center for studies for young indigenous Mayans from rural areas.
He was assassinated in February 1982, while standing on a ladder, repairing a wall of a school building.
Local authorities did not identify the gunmen.
Miller’s killing was one in a string of assassinations of priests and religious in the country, including that of Bl. Stanley Rother five months later.
Aware of the danger present to him in Guatemala, in one of his last letters before he died, Miller wrote: “I am personally weary of violence, but I continue to feel a strong commitment to the suffering poor of Central America. …the Church is being persecuted because of its option for the poor.”
“Aware of numerous dangers and difficulties, we continue working with faith and hope and trusting in God’s Providence. … I pray to God for the grace and strength to serve Him faithfully among the poor and oppressed in Guatemala. I place my life in His Providence. I place my trust in Him.”
The date of Miller’s beatification has not been announced but is expected to take place sometime in 2019.
In addition to Miller, Pope Francis Nov. 8 declared the martyrdom of Angelo Cuartas Cristobal and eight companions, alumni of the Seminary of Oviedo, Spain, who were killed in Oviedo between 1934-1937; and Mariano Mullerat i Soldevila, a layman and father, who was killed near Arbeca, Spain in 1936.
The pope also recognized miracles attributed to Venerable Edvige Carboni (1880-1952) and Benedetta Bianchi Porro (1936-1964), paving the way for their beatification.
The heroic virtue of nine other Catholics was also declared, advancing their causes along the path of beatification.
They are: Italian Bishop Giovanni Jacono (1873-1957); Filipino Bishop Alfredo Maria Obviar, founder of the Congregation of the Missionary Catechists of St. Teresa of the Child Jesus (1889-1978); Italian Fr. Giovanni Ciresola, founder of the Congregation of the Poor Servants of the Most Precious Blood-Cenacle of Charity (1902-1987); Italian Fr. Luigi Bosio (1909-1994); Italian Fr. Luigi Maria Raineri, member of the Congregation of the Clerics Regular of St. Paul (1895-1918); Spanish Sr. Maria Antonia di Gesu, member of the Discalced Carmelites (1700-1760); Spanish Sr. Arcangela Badosa Cuatrecasas, member of the Congregation of the Sisters of the Blessed Virgin Mary of Mount Carmel (1878-1918); Italian Sr. Maria Addolorata del Sacro Costato of the Congregation of the Sisters of the Passion of Jesus Christ (1920-1954); and Italian Lodovico Coccapani, lay member of the Secular Franciscan Order (1849-1931).
Reported by CNA 5 hours ago.
↧
More Pages to Explore .....
